

Author's Accepted Manuscript

Reduced cardiovascular fitness associated with exposure to clozapine in individuals with chronic schizophrenia

David D. Kim, Donna J. Lang, Ric M. Procyshyn, Melissa L. Woodward, Kai Kaufman, Randall F. White, William G. Honer, Darren E.R. Warburton



PII: S0165-1781(17)30782-5
DOI: <https://doi.org/10.1016/j.psychres.2018.01.029>
Reference: PSY11156

To appear in: *Psychiatry Research*

Received date: 30 June 2017
Revised date: 21 November 2017
Accepted date: 12 January 2018

Cite this article as: David D. Kim, Donna J. Lang, Ric M. Procyshyn, Melissa L. Woodward, Kai Kaufman, Randall F. White, William G. Honer and Darren E.R. Warburton, Reduced cardiovascular fitness associated with exposure to clozapine in individuals with chronic schizophrenia, *Psychiatry Research*, <https://doi.org/10.1016/j.psychres.2018.01.029>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Reduced cardiovascular fitness associated with exposure to clozapine in individuals with chronic schizophrenia

David D. Kim^{a,b}, Donna J. Lang^c, Ric M. Procyshyn^d, Melissa L. Woodward^c, Kai Kaufman^b, Randall F. White^d, William G. Honer^d, Darren E. R. Warburton^{b,e,*}

^a*Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada*

^b*Cardiovascular Physiology and Rehabilitation Laboratory, Physical Activity Promotion and Chronic Disease Prevention Unit, University of British Columbia, Vancouver, BC, Canada*

^c*Department of Radiology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada*

^d*Department of Psychiatry, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada*

^e*Experimental Medicine Program, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada*

* **Correspondence to:** Room 205, Unit II Osborne Centre, University of British Columbia, 6108 Thunderbird Boulevard, Vancouver, BC, V6T 1Z3 Canada, Tel.: (604) 822-4603; fax: (604) 822-9222; darren.warburton@ubc.ca

Abstract:

Studies show that individuals with schizophrenia have impaired cardiovascular fitness (i.e., low peak aerobic power (VO₂peak)). It is speculated that antipsychotics with adverse cardiovascular and metabolic profiles, in particular clozapine, have a significant impact on VO₂peak. In this cross-sectional study, we examined whether exposure to clozapine was associated with further reduced VO₂peak compared with non-clozapine antipsychotics. Thirty participants with chronic schizophrenia or schizoaffective disorder were divided into clozapine and non-clozapine groups. Mean daily doses of antipsychotics were standardized to chlorpromazine equivalents and haloperidol equivalents for antagonism of alpha₁- and alpha₂-adrenergic receptors. Participants completed an incremental-to-maximal symptom-limited exercise test on a cycle ergometer for the assessment of VO₂peak. The clozapine group demonstrated significantly lower VO₂peak than the non-clozapine group. Haloperidol equivalents for alpha-adrenergic receptor antagonism, but not chlorpromazine equivalents, demonstrated significant inverse associations with VO₂peak.

Download English Version:

<https://daneshyari.com/en/article/6811494>

Download Persian Version:

<https://daneshyari.com/article/6811494>

[Daneshyari.com](https://daneshyari.com)